Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma

A clinical trial related to cancer immunotherapy, retrieved from clinicaltrials.gov

Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT03409848

P921main subjectcancer immunotherapyQ2012719
P1050medical conditionesophageal neoplasmQ56014520
stomach neoplasmQ4335552
P2899minimum age18
P8363study typeinterventional studyQ78089383

Search more.